Zydus Lifesciences has received final clearance from the USFDA for its Deflazacort Oral Suspension (22.75 mg/mL) for the treatment of Duchenne Muscular Dystrophy in patients aged 5 years and older, which is a generic version of Emflaza Oral...
.png)
AbbVie has forwarded a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) that aims to get consent for an experimental treatment, Pivekimab sunirine (PVEK) for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
The suspicion of Coldrif cough syrup contamination has led to Immediate Inspection following reports of child fatalities in Madhya Pradesh and Rajasthan. Drug Controller General of India (DCGI) Dr Rajivsingh Reghuvanshi ordered an inspection...
.jpeg)
Fujifilm India has launched a digital radiology X-ray centre in the Community Health Centre (CHC) in Dholera, Gujarat
Johnson & Johnson today reported the results of new Phase 3 data for seltorexant, a novel selective orexin-2 receptor antagonist, as an add-on treatment for adults and elderly patients with major depressive disorder (MDD) and insomnia symptoms...
Agilus Diagnostics, the flagship provider of diagnostic services in India, is a wholly-owned subsidiary of Fortis Healthcare Ltd., and has made the announcement of the introduction of its AgilusEDGE Comprehensive Genomic Profile
Indoco Remedies Limited has announced that the US FDA inspected its Active Pharmaceutical Ingredients (API) manufacturing facility at Patalganga, Navi Mumbai and has concluded with zero Form 483 observations. This is evidence of Indoco'...
.jpeg)
Datavant, the healthcare data collaboration network, has declared its strategic collaboration with Indegene to improve the effectiveness of recruitment in complicated studies.
In an interaction with Thiruamuthan, Correspondent, India Pharma Outlook, Anjali Ajaikumar, Director, Milann Fertility & Birthing Hospital, discusses the rising infertility challenge, evolving fertility treatments, and innovations shaping personalize
Eli Lilly and Company announced promising topline findings from its ACHIEVE-3 Phase 3 study, revealing that their investigational GLP-1 receptor agonist, orforglipron, which is administered orally once a day, was associated with better results...
.jpg)
, CDSCO.jpg)